Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Enhertu 100 mg powder for concentrate for solution for infusion {equilateral_black_triangle}

Active Ingredient:
trastuzumab deruxtecan
Company:  
Daiichi Sankyo UK Limited See contact details
ATC code: 
L01FD04
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials HCP Med Info
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Patient Card: Enhertu

- This Patient Card has been provided to you because your doctor has prescribed you Enhertu. - This Patient Card helps you to identify symptoms of lung problems that you may experience with Enhertu. - Read this information before you start receiving Enhertu and before each infusion. - You should keep this card with you at all times and show it to any doctor you consult (for example if your regular doctor is unavailable or if you are travelling).

{pdf_link}

HCP Guide for Prevention of Product Confusion Medication Errors - Enhertu

{healthcare_pro_orange} For Healthcare Professionals

This HCP guide is a condition of the Marketing Authorisation for Enhertu. It serves to minimise the important potential risk of medication error in addition to the SmPC. HCPs should read it before prescribing and administering Enhertu (trastuzumab deruxtecan). Risk of confusion between Enhertu (trastuzumab deruxtecan) and other trastuzumab-containing products including Kadcyla (trastuzumab emtansine).

{pdf_link}

HCP Guide: Important Safety Information on ILD/Pneumonitis with treatment of Enhertu

{healthcare_pro_orange} For Healthcare Professionals

This HCP guide is: - provided for HCPs to read before prescribing and administering Enhertu - an important tool to ensure the early recognition and diagnosis of ILD/pneumonitis, to allow prompt and appropriate treatment and minimise serious outcomes - a reminder to distribute a Patient Card to any patient receiving Enhertu treatment for the first time or if asked for a new copy

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Daiichi Sankyo UK Limited
Company image
Address
1st Floor, Building 4, Uxbridge Business Park, Sanderson Road, Uxbridge, UB8 1DH, UK
Telephone
+44 (0) 800 028 5122
Medical Information Direct Line
+44 (0) 800 028 5122
Medical Information e-mail
[email protected]
Customer Care direct line
+44 (0) 800 028 5122
Out of Hours Telephone
+44 (0) 800 028 5122